Daily Low-Dose Subcutaneous Recombinant Interleukin-2 by Alternate Weekly Administration

Tagliaferri, P; Barile, Carmen; Caraglia, Michele; Guarrasi, Rosario; Morelli, Daniela; Ricciardi, Benjamin F.; Martignetti, Angelo; Librera, Mariateresa; Matano, Elide; Vecchia, Antonio Della; Catalano, Giuseppe; Famiani, M.; Palmieri, G.; Correale, Pierpaolo; Bianco, A

doi:10.1097/00000421-199802000-00011

Cited by 23 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…regimens of IL-2 or alternate routes of administration of IL-2 (s.c. injection, inhalation, etc.) to abrogate the toxicities (18–22) associated with IL-2 have resulted in lower response rates.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

Smith

Downey

Klapper

et al. 2008

Clinical Cancer Research

209

144

View full text Add to dashboard Cite

Purpose: To identify prognostic factors associated with survival beyond 4 years and overall response in patients with metastatic melanoma treated with high-dose bolus i.v. interleukin-2 (IL-2) given either alone or in combination with a variety of melanoma vaccines. Study Design: 684 consecutive patients with metastatic melanoma received high-dose bolus i.v. IL-2 either alone or in conjunction with a variety of melanoma vaccines. Treatments occurred between August 1, 1985 and January 1, 2006. Results: The overall objective response rate was 13% for patients receiving IL-2 alone and 16% for patients who received IL-2 with vaccine. In patients treated with IL-2 alone (n = 305) and IL-2 with vaccine (n = 379), having an objective response was associated with survival beyond 4 years (P < 0.0001). No pretreatment factors could be identified that were strongly associated with increased rate of objective response or long-term survival in patients receiving IL-2 alone. In patients receiving IL-2 with vaccines, there were increased response rates in patients with s.c. or cutaneous disease only and lower response rates with visceral disease only. Patients who received the gp100:209-217(210M) peptide plus IL-2 showed a strong trend to increased objective responses compared with IL-2 alone (22% versus 12.8%; P = 0.01) and also compared with patients who received a variety of vaccines that did not include this immunogenic peptide (13.8%; P = 0.009). Conclusion: IL-2 can produce a modest response rate in patients with metastatic melanoma including patients with durable complete responses. S.c. or cutaneous disease only and vaccination with gp100:209-217(210M) peptide was associated with significant increase in response rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

Smith

Downey

Klapper

et al. 2008

Clinical Cancer Research

209

144

View full text Add to dashboard Cite

show abstract

“…Using high-dose IL-2 (720,000 IU/kg) alone appears to be more effective than low-dose IL-2. 48 In numerous trials IL-2 has been used alone or in combination with other cytokines (IFN-α , IL-1, IL-4, IL-12, TNF, TNF-γ , and FLT3L) and with other chemotherapeutic agents (cisplatin, dacarbazine, carmustine, vinblastine). None of these combinations was associated with enhanced survival rate.…”

mentioning

confidence: 99%

Malignant mucosal melanoma of the head and neck — a review

Lengyel

Gilde

Remenár

et al. 2003

Pathol. Oncol. Res.

View full text Add to dashboard Cite

“…This treatment was well tolerated, with no grade II adverse effects. However, although the response rate was 33.3% in patients with renal cell carcinoma, no major responses were observed in patients with malignant melanoma or colorectal cancer 8…”

Section: Cytokinesmentioning

confidence: 88%

Melanoma Immunotherapy

Sivendran

Glodny

Pan

et al. 2010

Mount Sinai J Medicine

View full text Add to dashboard Cite

Melanoma immunotherapy has been an area of intense research for decades, and this work is now yielding more tangible results for patients. Work has focused on 4 main areas: cytokine therapy, administration of immune-modulating antibodies, adoptive T-cell therapy, and vaccines. Cytokine therapy is an established treatment for advanced melanoma, and immune-modulating antibodies have recently emerged as an exciting new area of drug development with efficacy now established in a phase III trial. Adoptive T-cell therapy provides the proof of principle that T cells can attack and eliminate tumors. It has been challenging, however, to adapt this treatment for widespread use. Vaccines have generally yielded poor results, but intratumor pathogen-based strategies have shown encouraging results in recent trials, perhaps due to stronger immune stimulation. A review of the field of melanoma immunotherapy is provided here, with emphasis on those agents that have reached clinical testing. Novel strategies to induce the immune system to attack melanomas are reviewed. In the future, it is envisioned that immunotherapy will have further application in combination with cytotoxic and targeted therapies.

show abstract

Daily Low-Dose Subcutaneous Recombinant Interleukin-2 by Alternate Weekly Administration

Cited by 23 publications

References 10 publications

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

Malignant mucosal melanoma of the head and neck — a review

Melanoma Immunotherapy

Contact Info

Product

Resources

About